Immune Checkpoints Activators - Competitive Landscape, Technology and Pipeline Analysis 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Immune Checkpoints Activators - Competitive Landscape, Technology and Pipeline Analysis, 2017" report to their offering.

Immune Checkpoints Activators - Competitive Landscape, Technology and Pipeline Analysis, 2017 provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Immune Checkpoints Activators.

This report provides information on the therapeutic development based on Immune Checkpoints Activators mechanism of action dealing with around 20+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs.

This report also assesses the Immune Checkpoints Activators therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 20+ active companies involved in the therapeutic development of the products.

For more information about this report visit http://www.researchandmarkets.com/research/8d8535/immune

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs